The Top COVID-19 Vaccine Stocks to Strongly Consider


We may be nearing a coronavirus vaccine.

Moderna just received another round of U.S. funding for its vaccine in the amount of $472 million.  According to SVB Leerink analysts, that commitment will be used to fund a Phase 3 trial for Moderna’s vaccine, which is “set to begin immediately,” as quoted by MarketWatch.

The trial is expected to enroll about 30,000 adults and will evaluate if the vaccine can prevent symptomatic COVID-19 after two doses.  The volunteers will receive two 100 microgr...

Register Now

The Daily Chart Newsletter is available only to members of this site. Register now for FREE. No cost, no obligation, join today.

Already a member? Login below, or click here to register now for free.